Glyx Therapeutics
Glyx Therapeutics is a biotechnology company developing first-in-class, orally available, brain-penetrant small molecules that target the tau protein to treat tauopathies such as Alzheimer’s disease, Progressive Supranuclear Palsy, and Pick’s disease. Its lead candidate, Mal16diS, has demonstrated in vivo proof of concept in a tauopathy mouse model with confirmed blood-brain barrier penetration and a favorable early safety profile, positioning it as a disease-modifying approach where none currently exist.
- Biotechnology
- Drug Discovery & Therapeutics
- Healthcare Technology
- Software Only
Funding
Founders
Product
Problem
Neurodegenerative diseases such as Alzheimer’s disease, Progressive Supranuclear Palsy (PSP), and Pick’s disease are driven by the pathological aggregation of the tau protein, yet no disease-modifying therapies currently exist to address this root cause. Existing treatments focus on symptom management rather than halting or reversing the underlying neurodegeneration, leaving patients and families with limited options for preserving cognitive function and quality of life.
Solution
Glyx Therapeutics is developing first-in-class, orally available, brain-penetrant small molecules designed to target tau protein aggregation at its root, offering a disease-modifying approach for tauopathies. The lead candidate, Mal16diS, works through multiple mechanisms of action against tau and has demonstrated in vivo proof of concept in the rTg4510 tauopathy mouse model, with confirmed blood-brain barrier penetration and a favorable early safety profile. The company combines green chemistry with cutting-edge research to create sustainable, accessible therapeutics, aiming to become a leader in tauopathy care through precision medicine. By advancing this lead candidate toward clinical proof-of-concept, Glyx Therapeutics seeks to transform patient outcomes and redefine how neurodegenerative diseases are treated.
Target Audience
Glyx Therapeutics primarily targets pharmaceutical partners, venture funds, business angels, and family offices for investing in and licensing its preclinical tauopathy program, while the ultimate end users of its therapies are patients affected by tauopathies including Alzheimer’s disease, PSP, and Pick’s disease.
Features
- Orally available, brain-penetrant small molecule designed to cross the blood-brain barrier and target tau protein directly
- Lead candidate Mal16diS with in vivo proof of concept validated in the rTg4510 tauopathy mouse model
- First-in-class mechanism targeting the pathological aggregation of tau, the primary driver of tauopathies and Alzheimer’s disease
- Favorable early safety profile supporting progression toward first-in-human studies
- Green chemistry-based sustainable synthesis approach integrated throughout pharmaceutical R&D
- Staged, indication-split licensing model spanning rare tauopathies and Alzheimer’s disease for industrial partnerships